Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Osteoporosis (Ibandronic acid - Osteoporosis)

Records returned : 17 (on 29 May 2025 at 11:49:32). Return to search results for ' Osteoporosis '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off-label use. Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

Drug:

Indication :

Osteoporosis

Status :

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

Drug:

Indication :

Osteoporosis

Status :

Formulations :

Not Specified

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

3. Ibandronic acid

Drug:

Ibandronic acid

Indication :

Osteoporosis

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

150mg tablets
(note - 50mg tablets are not licensed for this indication)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

4. Ibandronic acid

Drug:

Ibandronic acid

Indication :

Osteoporosis

Status :

Red

Formulations :

Intravenous infusion

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

5. Alendronic acid

Drug:

Alendronic acid

Indication :

Osteoporosis

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Preferred

ONCE WEEKLY tablets

ONCE DAILY tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

7. Alendronic acid

Drug:

Alendronic acid

Indication :

Osteoporosis

Status :

Green (see narrative)

Formulations :

Oral solution

Restrictions / Comments:

Important

Reserve for patients with swallowing difficulties.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

8. Alendronic acid

Drug:

Alendronic acid

Indication :

Osteoporosis

Status :

Green (see narrative)

Formulations :

Effervescent tablets

Restrictions / Comments:

Important

Reserve for patients who have tried alendronate and/or risedronate but are unable to swallow tablets (as opposed to patients with swallowing difficulties in whom the oral solution may be appropriate).

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

6. Risedronate sodium

Drug:

Risedronate sodium

Indication :

Osteoporosis

Status :

Green

Formulations :

Tablets

Restrictions / Comments:

Important

Preferred

Weekly tablets are 35mg. Daily tablets are 5mg.
NOTE - 30mg tablets are licensed for Paget's disease only

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

9. Denosumab

Drug:

Denosumab

Indication :

Osteoporosis

Status :

Green (see narrative)

Formulations :

Subcutaneous injection (sc)

Restrictions / Comments:

Important

Rheumatology only in secondary care.
Restricted to use in patients for whom bisphosphonates are unsuitable.

Patients with a CKD of 4 or 5 and patients with a T-score of < -4.5 to remain under specialist care.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

NICE

10. Raloxifene hydrochloride

Drug:

Raloxifene hydrochloride

Indication :

Osteoporosis

Status :

Green (see narrative)

Formulations :

Tablets

Restrictions / Comments:

Important

Only recommended as an option in secondary prevention where other options have been exhausted.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

11. Abaloparatide

Drug:

Abaloparatide

Indication :

Osteoporosis

Status :

Red

Formulations :

Subcutaneous injection (sc)

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

12. Romosozumab

Drug:

Romosozumab

Indication :

Osteoporosis

Status :

Red

Formulations :

Injection

Restrictions / Comments:

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

ICB

NICE

13. Strontium ranelate

Drug:

Strontium ranelate

Indication :

Osteoporosis

Status :

Red

Formulations :

Sachets (granules)

Restrictions / Comments:

Important

Rheumatology only. Reserved for severe osteoporosis in patients for whom other treatment options are not suitable.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines SPC

14. Teriparatide

Drug:

Teriparatide

Indication :

Osteoporosis

Status :

Red

Formulations :

Injection

Restrictions / Comments:

Important

Post-menopausal osteoporosis in women. Rheumatology only.
See separate entry for use in men and juveniles.
Biosimilar teriparatide is recommended. Prescribe by brand.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :